<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581071</url>
  </required_header>
  <id_info>
    <org_study_id>TS143-01-02</org_study_id>
    <secondary_id>JapicCTI-163383</secondary_id>
    <nct_id>NCT03581071</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease</brief_title>
  <official_title>Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and
      hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single
      administration of TS-143.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2016</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">July 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>8 days</time_frame>
    <description>To evaluate the safety of TS-143 given single administration in CKD patients by incidence of adverse events which include abnormal electrocardiograms, vital signs, and clinical laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of unchanged form (ng/mL)</measure>
    <time_frame>7 days</time_frame>
    <description>The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) were calculated by dose group and evaluation timing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretions of unchanged form (ng/mL)</measure>
    <time_frame>24 hours</time_frame>
    <description>The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) for the total urinary excretion (amount and fraction) were summarized by dose group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum EPO concentration</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte count</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma vascular endothelial growth factor (VEGF) concentration</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Step1:1mg in non-dialysis subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step2-1:1mg in hemodialysis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step2-2:6mg in non-dialysis subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step3-1:11㎎ in hemodialysis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step3-2:11㎎ in non-dialysis subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-143</intervention_name>
    <arm_group_label>Step1:1mg in non-dialysis subject</arm_group_label>
    <arm_group_label>Step2-1:1mg in hemodialysis subjects</arm_group_label>
    <arm_group_label>Step2-2:6mg in non-dialysis subject</arm_group_label>
    <arm_group_label>Step3-1:11㎎ in hemodialysis subjects</arm_group_label>
    <arm_group_label>Step3-2:11㎎ in non-dialysis subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum concentration of erythropoietin (EPO): &lt;50 mIU/mL at screening test 1, 2, or 3

          -  Transferrin saturation ≥ 20% or ferritin ≥ 100 ng/mL at screening test 1

          -  Subjects meeting any of the following criteria

               1. Subjects who has not used erythropoiesis-stimulating agent (ESA) ≥ eight weeks
                  from screening test 1

               2. Subjects who has used ESA, other than epoetin beta pegol, ≥ four weeks from
                  screening test 1 and has met all of the following criteria A) to C).

        A)The total ESA dosage for each week could be changed within a range of 50%, compared to
        the total ESA dosage for one week before screening test 1, for four weeks before screening
        test 1 B)Acceptable to discontinue ESA the day following screening test 1 to Follow-up 2
        C)The fluctuating range of Hb concentration between screening tests 1 and 2 is within ±0.5
        g/dL per week (the same criteria applied between screening test 2 and 3)

          -  Subjects who receive an explanation about the study before participating in the study
             and can understand the contents and are willing and able to provide written consent.

        &lt;Criteria for ND subjects&gt;

          -  CKD subjects who never received dialysis and do not need to receive dialysis during
             the study period.

          -  Subjects with an Hb concentration at screening test 1 (ESA present at screening test
             2) ≥ 10.0 g/dL to &lt; 13.0 g/dL.

          -  Subjects with an eGFR at screening test 1 ≥ 15 mL/min/1.73m^2 to &lt; 45 mL/min/1.73m^2.

        &lt;Criteria for HD subjects&gt;

          -  Subjects who received hemodialysis (including diafiltration) three times per week ≥ 12
             weeks from acquisition consent.

          -  Subjects with an Hb concentration at screening test 1 (ESA present at screening test
             2) ≥ 10.0 g/dL to &lt; 12.0 g/dL.

        Exclusion Criteria:

          -  Subjects with anemia other than that caused by CKD.

          -  Subjects who have severe infection, systemic hematopathy (e.g. myelodysplastic
             syndrome, hemoglobinopathy), peptic ulcer or clear hemorrhagic lesion such as
             gastrointestinal hemorrhage

          -  Subjects with immune disorder with severe inflammation

          -  Subjects with uncontrolled secondary hyperparathyroidism

          -  Subjects who already had or will have a kidney transplantation

          -  Subjects who have a complication which requires treatment such as proliferative
             retinopathy, macular edema, or macular degeneration. Or, subjects who had a
             complication which required treatment such as proliferative retinopathy, macular
             edema, or macular degeneration within 12 months from screening test 1

          -  Subjects with congestive heart failure

          -  Subjects with a medical history of thrombotic disease in the six months from screening
             test 1

          -  Subjects with uncontrolled blood pressure; SBP &gt; 170 mmHg or DBP &gt; 100 mmHg at
             screening test 1 (ESA present, screening tests 1 and 2), (HD subject, evaluated before
             dialysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Okuyama</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Shinfuku A, Shimazaki T, Fujiwara M, Sato F, Watase H, Numazaki T, Kawakita Y, Mutoh M, Yamasaki H, Takayama N, Kato S, Sugimoto T, Maruyama J. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers. Am J Nephrol. 2018;48(3):157-164. doi: 10.1159/000492181. Epub 2018 Sep 3.</citation>
    <PMID>30176654</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis, CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

